Analysis of therapeutic effect of cell reduction combined with intraperitoneal thermoperfusion chemotherapy in treatment of peritoneal pseudomyxoma

Table 2 186 patients with pseudomyxoma were treated with cell reduction combined with intraperitoneal hyperthermic chemotherapy

Incidence of complications	n (%)
Death 30 days after surgery	5 (2.7)
Death 90 days after surgery	8 (4.3)
Further surgery is required	3 (1.6)
Grade III-IN complications	80 (43.0)
Gastrointestinal anastomotic leakage	4 (2.2)
Urinary system complications (ureteral injury, urinary leakage, etc.)	1 (0.5)
Abdominal bleeding	4 (2.2)
Abdominal infection	8 (4.3)
Wound infection	2 (1.1)
Sepsis or sepsis	1 (0.5)
Urinary tract infection	1 (0.5)
Ascites	4 (2.2)
Pneumonia	10 (5.4
Pneumothorax	2 (1.1)
Cardiac insufficiency or heart failure	2 (1.1)
Renal insufficiency	1 (0.5)
Hepatic insufficiency	19 (10.2)
Septic shock	2 (1.1)
Hemorrhagic shock	2 (1.1)
Albumin reduction	14 (7.5)
Hemoglobin reduction	51 (27.4)
Thrombocytopenia	2 (1.1)
Electrolyte disturbance	21 (11.6)
Coagulopathy	11 (5.9)